Nintedanib 100mg Capsules (Bronchonib): One Molecule Blocking Three Receptor Families

Overview

Kinase inhibitors are usually praised for selectivity. This one is valued for the opposite quality — it engages three separate growth factor receptor families at once, and the therapeutic effect emerges from that deliberate breadth rather than despite it.

Bronchonib supplies nintedanib as 100 mg soft capsules in packs of 30. The triple-receptor profile is also why the same molecule appears in two clinical settings that look unrelated on the surface: tumour vasculature and lung scarring.

How It Works

Nintedanib binds the ATP pockets of vascular endothelial growth factor receptors 1 through 3, fibroblast growth factor receptors 1 through 3, and platelet-derived growth factor receptors alpha and beta. Each family governs a different cell type in the tissue microenvironment. VEGFR signalling directs endothelial cells to form new vessels. FGFR signalling sustains fibroblast proliferation and survival. PDGFR signalling recruits pericytes and drives their differentiation toward a myofibroblast phenotype.

Blocking any one family in isolation invites compensation, because the remaining pathways can substitute for the missing signal. Simultaneous occupancy removes that redundancy. In fibrotic lung tissue the consequence is reduced fibroblast proliferation and less myofibroblast conversion, which slows the deposition of extracellular matrix; in tumour tissue the same triple blockade restricts the vascular and stromal support a growing mass depends on.

Indications

Nintedanib is established in idiopathic pulmonary fibrosis, in chronic fibrosing interstitial lung diseases with a progressive phenotype, and in systemic sclerosis-associated interstitial lung disease. In oncology it has been registered in some markets in combination with docetaxel for locally advanced or metastatic non-small cell lung cancer of adenocarcinoma histology after first-line chemotherapy. Applicable indications depend on local registration.

Dosage & Administration

Capsules are swallowed whole with food, roughly twelve hours apart, and are never chewed or opened. The 100 mg strength serves both as a reduced maintenance dose where the higher strength is not tolerated and as a step in dose modification. Liver function is checked before starting and monitored during treatment, and diarrhoea is managed early to preserve dose intensity. Anticoagulant use requires review before initiation. The prescribing specialist sets the final schedule.

Storage & Sourcing

Soft capsules are stored below 25 °C in the original blister, protected from moisture and heat, which the gelatine shell tolerates poorly. No refrigeration is needed. Since therapy is long-term and often continues for years, buyers plan supply against sustained monthly consumption rather than episodic demand.

FAQ

Q: What does blocking three receptor families achieve that a selective agent cannot?

A: It removes pathway redundancy — endothelial, fibroblast and pericyte signalling can each compensate for the others, so simultaneous inhibition is required to suppress the network.

Q: How does the same mechanism serve both fibrosis and oncology use?

A: Fibroblast and vascular signalling underpin both scar formation and tumour stromal support, so one blockade profile addresses two different pathological processes.

Q: Why must the capsule be taken with food and swallowed intact?

A: Food improves absorption of the soft-capsule formulation, and breaking the shell disrupts the delivery system and increases gastrointestinal irritation.

Q: Which laboratory parameter is watched most closely during treatment?

A: Hepatic transaminases and bilirubin, with baseline testing before initiation and scheduled monitoring thereafter.